Gibson P, Henry D, Francis L, Cruickshank D, Dupen F, Higginbotham N, Henry R, Sutherland D
John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
BMJ. 1993 Jun 5;306(6891):1514-8. doi: 10.1136/bmj.306.6891.1514.
To determine whether the availability of beta 2 agonist inhalers without prescription leads to undertreatment of asthma.
Cross sectional study of adequacy of treatment in asthmatic subjects who purchased beta 2 agonist inhalers and subjects who obtained inhalers by prescription.
Community pharmacies in New South Wales, Australia.
403 eligible consecutive asthmatic subjects aged 13 to 55 purchasing salbutamol metered dose inhalers over the counter or by prescription; 197 attended for follow up and spirometry and 139 returned 14 day symptom, peak flow, and medication diaries.
Severity of asthma assessed on frequency of day time and night time wheezing, frequency of inhaler use, and peak expiratory flow rates. Adequacy of treatment according to published guidelines.
Of the 139 patients who completed the diary 83, (60%) purchased their inhalers without prescription and 83 were undertreated. The characteristics of patients in the prescription and purchasing groups were similar. Multiple logistic regression analysis identified use of non-prescribed salbutamol as being associated with a 2.9-fold increase in the odds of undertreatment (95% confidence interval 1.3 to 6.8). Smoking increased the odds of undertreatment (3.3, 1.2 to 9.5) and use of a peak flow meter reduced the odds (0.11, 0.04 to 0.34). Adjustment for frequency of consultation made use of non-prescription salbutamol insignificant (1.4, 0.55 to 3.8). Attitudes to services provided by doctors and pharmacists were favourable and not associated with undertreatment.
Over the counter purchase of salbutamol is associated with infrequent consultation with doctors and undertreatment of asthma.
确定无需处方即可获得β2激动剂吸入器是否会导致哮喘治疗不足。
对购买β2激动剂吸入器的哮喘患者和通过处方获得吸入器的患者的治疗充分性进行横断面研究。
澳大利亚新南威尔士州的社区药房。
403名年龄在13至55岁之间符合条件的连续哮喘患者,他们通过非处方或处方购买沙丁胺醇定量气雾剂;197人接受了随访和肺活量测定,139人返回了14天的症状、呼气峰值流速和用药日记。
根据白天和夜间喘息频率、吸入器使用频率和呼气峰值流速评估哮喘严重程度。根据已发表的指南评估治疗的充分性。
在完成日记的139名患者中,83名(60%)非处方购买吸入器,且83名治疗不足。处方组和购买组患者的特征相似。多因素logistic回归分析确定,使用非处方沙丁胺醇与治疗不足几率增加2.9倍相关(95%置信区间1.3至6.8)。吸烟增加了治疗不足的几率(3.3,1.2至9.5),而使用呼气峰值流量计则降低了几率(0.11,0.04至0.34)。对就诊频率进行调整后,使用非处方沙丁胺醇变得不显著(1.4,0.55至3.8)。对医生和药剂师提供的服务的态度良好,且与治疗不足无关。
非处方购买沙丁胺醇与看医生次数少和哮喘治疗不足有关。